Oxford Nanopore shares fall as revenue grows in 2025
Oxford Nanopore Technologies PLC on Monday reported revenue growth and a similar loss in 2025 as it reaffirmed its targets for 2027 and 2028.
The Oxford-based specialist in DNA and RNA sequencing technologies said pretax loss narrowed a notch to £139.9 million in 2025 from £140.0 million in 2024.
However, adjusted loss before interest, tax, depreciation and amortisation narrowed by 26% to £86.7 million in 2025 from £117.9 million in 2024.
Revenue rose 22% to £223.9 million from £183.2 million.
The firm noted ‘strong demand across Research and Applied markets, with particularly rapid growth in Clinical, BioPharma and Applied Industrial segments, reflecting increasing adoption where Oxford Nanopore’s richer, faster data delivers clear value over legacy and alternative approaches. Growth was delivered across all geographies, product types and customer segments, underlining the resilience and diversity of the group’s revenue base.’
Cost of sales increased 19% to £92.6 million from £77.8 million. Selling, general and administrative expenses increased at the same pace to £188.9 million from £158.8 million.
Looking ahead, Oxford Nanopore said for 2026 it expects revenue to grow by between 21% and 25% on a constant currency basis. Back in September, the firm guided for over 30% revenue growth between 2024 and 2027, at constant currency on a compound annual growth rate.
Further, it expects adjusted operating costs to be up to 5% higher than in 2025.
The company reaffirmed its goal to reach adjusted Ebitda breakeven in 2027 and become cash flow positive in 2028.
Chair Duncan Tatton-Brown said: ‘With a well-managed leadership transition underway, refined strategic planning processes and continued focus on disciplined execution, the board believes the group is well positioned to deliver sustainable value for shareholders and wider stakeholders.’
Oxford Nanopore shares fell 14% to 114.20 pence each on Monday afternoon in London.
Copyright 2026 Alliance News Ltd. All Rights Reserved.